Kevin Waldron and I are organising a special “Microbial metal homeostasis: impacts on pathogenicity” session at next year’s Microbiology Society meeting (https://www.microbiologysociety.org/event/annual-conference/annual-conference-2018.html).
It will be held in Birmingham on the 11th of April. The entire conference is from the 10th-13th but it is also possible to register on a day-by-day basis.
There are opportunities for offered talks, so please encourage any interested PIs, post-docs and students to submit an abstract.
University of Aberdeen (UK)
The BioSys-Biological Systems, Functional & Integrative Genomics PhD Programme (PhD in Biology/Biochemistry) has opened its 2018 edition project calls (https://biosyssite.wordpress.com/) , with several projects available.
APPLICATION DEADLINE: 24th October 2017
Specifically, we call your attention to the following project on Alzheimer’s Disease pathomechanisms, involving our laboratories in Lisbon (Portugal) and Limerick (Ireland)
The role of secondary modification of S100B in protein aggregation and its influence on Alzheimer’s disease pathology.
Keywords: AD; Protein aggregation, trace metals; inflammation; animal models; structural biophysics; metal-binding proteins; neuronal cell cultures; fluorescence bioimaging; biochemistry; neurodegeneration
In this project, we want to investigate the interrelationship between the S100B pro-inflammatory cytokine, trace metal homeostasis and protein aggregation in a physiological context, and in the background of Alzheimer’s disease (AD). The project will combine in vitro and in vivo approaches and will be developed jointly at the University of Lisbon (Portugal) and University of Limerick (Ireland) under the joint supervision of active supervisors in dynamic laboratories which with an established collaborative track record. Selected candidate will be awarded a stipend for the duration of the PhD.
Project Supervisors: Cláudio M. Gomes (Lisbon) and Andreas Grabrucker (Limerick)
Cláudio M. Gomes (BioISI/FCUL, Lisbon, Portugal)
Head of the Protein Folding and Misfolding Laboratory
Andreas Grabrucker (University of Limerick / Bernal Institute, Limerick, Ireland)
Head of the Cellular Neurobiology & Neuro-Nanotechnology Laboratory
Further information anon applications and on the BioSys PhD programme
Queen’s University Belfast’s Dr Imre Lengyel discusses new research which could pave the way to earlier treatment strategies for age-related macular degeneration.
The leading cause of sight loss in development countries, age-related macular degeneration (AMD) is roughly twice as common as Alzheimer’s among older people – and growing. By 2020, it is projected to affect some 196 million people, rising to a massive 288 million by 2040. But while AMD can now be treated with an injection of anti-vascular endothelial growth factor (VEGF), there is currently no treatment available for the most common dry form of AMD.
More information can be found here.